Biblio
“Neuroprotective Effect of Phloretin in Rotenone-Induced Mice Model of Parkinson's Disease: Modulating mTOR-NRF2-p62 Mediated Autophagy-Oxidative Stress Crosstalk.”, J Alzheimers Dis, vol. 94, no. s1, pp. S109-S124, 2023.
, “Non-Pharmacological Interventions for Feeding and Eating Disorders in Persons with Dementia: Systematic Review and Evidence Summary.”, J Alzheimers Dis, vol. 94, no. 1, pp. 67-88, 2023.
, “A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora.”, J Alzheimers Dis, vol. 94, no. s1, pp. S227-S239, 2023.
, “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
, “Odor Discrimination as a Marker of Early Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 3, pp. 1169-1178, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay.”, J Alzheimers Dis, vol. 94, no. s1, pp. S399-S428, 2023.
, “Phonological and Semantic Fluency in Alzheimer's Disease: A Systematic Review and Meta-Analysis.”, J Alzheimers Dis, vol. 95, no. 1, pp. 1-12, 2023.
, “The PI3K/AKT Signaling Pathway and Caspase-3 in Alzheimer's Disease: Which One Is the Beginner?”, J Alzheimers Dis, vol. 92, no. 2, pp. 391-393, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?”, J Alzheimers Dis, vol. 92, no. 3, pp. 799-801, 2023.
, “PM2.5 and Dementia in a Low Exposure Setting: The Influence of Odor Identification Ability and APOE.”, J Alzheimers Dis, vol. 92, no. 2, pp. 679-689, 2023.
, “Poor Oral Health as a Risk Factor for Dementia in a Swedish Population: A Cohort Study with 40 Years of Follow-Up.”, J Alzheimers Dis, vol. 92, no. 1, pp. 171-181, 2023.
, “Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.”, J Alzheimers Dis, vol. 96, no. 2, pp. 429-437, 2023.
, “Preventing Neurocognitive Decline in Adults Aging with HIV: Implications for Practice and Research.”, J Alzheimers Dis, vol. 95, no. 3, pp. 753-768, 2023.
, “Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Resveratrol Mediated Regulation of Hippocampal Neuroregenerative Plasticity via SIRT1 Pathway in Synergy with Wnt Signaling: Neurotherapeutic Implications to Mitigate Memory Loss in Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S125-S140, 2023.
, “The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review.”, J Alzheimers Dis, vol. 94, no. s1, pp. S45-S66, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S187-S202, 2023.
,